Carcinoma clinical trials at UC Health
2 in progress, 2 open to new patients
open to eligible people ages 18–80
This is a single center, open-label phase IIA study that investigates the preliminary efficacy of TATE treatment of liver cancer followed by a PD-1 checkpoint inhibitor (either nivolumab or pembrolizumab). At least two cohorts will be enrolled, one for patients with hepatocellular carcinoma (HCC) and the other with metastatic colorectal cancer (mCRC).
at UC Irvine
open to eligible people ages 12 years and up
Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3.